G3 Neuroendocrine Tumours and Carcinomas: Clinicopathological Features for Distinct Entities
Introduction: The 2019 WHO subclassified the grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) into neuroendocrine carcinoma (NEC) or tumors (G3 NET). Yet, few data exist on clinical and treatment profiles for G3 NET.
Aim(s): To evaluate the clinicopathological (CP) characteristics of G3 GEP NET and NEC.
Materials and methods: We retrospectively collected CP data of all G3 GEP NEN patients (pts) from 2000 to 2019. Cases with available tumor tissues were reviewed and reclassified according to WHO 2017. Survival from treatment start was the primary endpoint.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Taboada R
To read the full abstract, please log into your ENETS Member account.